Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Colospan's Greece-Cyprus CG-100 deal shows a capital-light route into Europe

Eocene's subsidiary hands exclusive rights for its CE-marked bypass device to Hospital Line SA, a small deal that sits within a wider run of asset-light moves by small-cap biotechs.

15 Nov 2026 · CompePharma editorial

What happened

On 10 November, EoCene Ltd. (EOCN) said its subsidiary Colospan has granted Hospital Line SA exclusive rights to market the CE-marked CG-100 intraluminal bypass device in Greece and Cyprus. It is Colospan's first European distribution agreement for the product.

The material available does not include financial terms, such as upfront payments, minimums, milestones or contract length. It also gives no sales expectations. The deal should therefore be read as a market-access step, not a revenue event. What is confirmed is the structure: exclusive, regional, distributor-led, and built on a product that already carries a CE mark.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →